MedTrace Logo

An Ethnobridging TriaL of AGA2118 in Healthy Japanese, Chinese, and Caucasian ParticipantS (ATLAS)

NCT07361354 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2026-07-08

No results posted yet for this study

Summary

This study will evaluate the effects of a single dose of AGA2118 in Japanese, Chinese, and Caucasian participants

Conditions

  • Healthy Participants
  • Pharmacokinetic Study

Interventions

DRUG

AGA2118

Participants will receive AGA2118 administered by subcutaneous injection

Sponsors & Collaborators

  • Angitia Incorporated Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-01-05
Primary Completion
2026-09-30
Completion
2026-09-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07361354 on ClinicalTrials.gov